•
Elvitegravir is an experimental
integrase inhibitor being developed by Gilead Sciences.
•
After HIV's genetic material
is deposited inside a cell, its RNA must be converted (reverse transcribed) into
DNA. A viral enzyme called integrase then helps to hide HIV's DNA inside the cell's
DNA. Once this happens, the cell can begin producing genetic material for new
viruses. Integrase inhibitors, such as elvitegravir, are designed to block the
activity of the integrase enzyme and to prevent HIV DNA from entering healthy
cell DNA.
•
Elvitegravir will need to
be used in combination with other drugs. Clinical trials will evaluate its effect
in combination with other drugs, including those currently approved for the treatment
of HIV.
